Tilray Brands (TLRY) Asset Writedowns and Impairment (2017 - 2025)
Tilray Brands (TLRY) posted Asset Writedowns and Impairment of -$699.2 million for Q2 2025, down 200.0% on a QoQ basis from $699.2 million in Q1 2025.
Tilray Brands (TLRY) Asset Writedowns and Impairment (2017 - 2025) Analysis & Trends
Tilray Brands' Asset Writedowns and Impairment history runs 8 years deep, the most recent figure standing at -$699.2 million for Q2 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to -$699.2 million in Q2 2025, while the trailing twelve-month figure through Feb 2025 was $1.6 billion (down 27.58% YoY) and the FY2023 annual result came in at $934.0 million, up 146.93% from the prior year.
- Asset Writedowns and Impairment was -$699.2 million for Q2 2025 at Tilray Brands, down from $699.2 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $934.0 million in Q1 2023 and bottomed at -$699.2 million in Q2 2025.
- A 4-year average of $363.1 million and a median of $532.7 million in 2022 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2021 — Asset Writedowns and Impairment sank 105.43% — and 2022, when it surged 45595.78%.
- Tilray Brands' Asset Writedowns and Impairment stood at -$805000.0 in 2021, then jumped by 45595.78% to $366.2 million in 2022, then surged by 140.01% to $879.0 million in 2023, then tumbled by 179.55% to -$699.2 million in 2025.
- Business Quant data shows TLRY's Asset Writedowns and Impairment at -$699.2 million in Q2 2025, $699.2 million in Q1 2025, and $879.0 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2025 | -699.24 Mn |
| May 31, 2025 | -699.24 Mn |
| Feb 28, 2025 | 699.24 Mn |
| Feb 28, 2025 | 699.24 Mn |
| May 31, 2023 | 879.00 Mn |
| May 31, 2023 | 879.00 Mn |
| Feb 28, 2023 | 934.00 Mn |
| Feb 28, 2023 | 934.00 Mn |
| May 31, 2022 | 366.24 Mn |
| May 31, 2022 | 366.24 Mn |
| May 31, 2021 | -805,000.00 |
| May 31, 2021 | -805,000.00 |
| May 31, 2020 | 14.82 Mn |
| May 31, 2020 | 14.82 Mn |
| Mar 31, 2020 | 46,000.00 |
| Mar 31, 2020 | 46,000.00 |
| Sep 30, 2019 | -275,000.00 |
| Sep 30, 2019 | -275,000.00 |
| May 31, 2019 | 57.19 Mn |
| May 31, 2019 | 57.19 Mn |